BioMarin Pharmaceutical Inc.’s (BMRN) phase 2 proof-of-concept and dose finding study of Vosoritide in children with achondroplasia has demonstrated a 50% increase in mean annualized growth velocity in 15 ug/kg/daily dose group. Achondroplasia is the most common form of human dwarfism.